Intuitive Surgical, Inc. (ISRG)

Intuitive Surgical's stock price has experienced volatility in the past six months, partly due to concerns about the impact of tariffs. In April 2025, Intuitive announced strong financial results for Q1 2025, with worldwide da Vinci procedures growing approximately 17% compared to Q1 2024, and Barclays issued an "Overweight" rating. In May 2025, the company won FDA clearance for a new indication for its da Vinci single port (SP) system and reported exceeding revenue and adjusted earnings per share expectations. In June 2025, Deutsche Bank issued a "Sell" rating. In July 2025, Intuitive reported robust second-quarter financial results, but the stock declined due to concerns about tariffs impacting the business; the da Vinci 5 system also received CE mark approval in Europe. In August 2025, RBC Capital issued an "Outperform" rating. In September 2025, the stock has been down 17% since January 2025, nearing its 52-week lows. In October 2025, BTIG issued a "Buy" rating, and analysts predict a potential return of 8.77% for the month.

Intuitive Surgical's business is subject to seasonal fluctuations. Sales of da Vinci Surgical Systems tend to be heaviest during the third month of each fiscal quarter and heavier in the fourth fiscal quarter, with lighter sales in the first and third fiscal quarters. The company has historically experienced lower procedure volume in the first and third fiscal quarters and higher procedure volume in the second and fourth fiscal quarters. The company's business model helps to offset the lumpiness of capital sales, ensuring more predictable financial performance.

Intuitive Surgical, Inc. is a global leader in robotic-assisted, minimally invasive surgery. Founded in 1995, the company's flagship product is the da Vinci Surgical System. The da Vinci Surgical Systems enable surgeons to perform complex procedures with enhanced precision, dexterity, and control. The Ion Endoluminal System extends Intuitive Surgical's offerings into diagnostic endoluminal procedures. The company generates revenue from the sale of instruments and accessories used with its da Vinci systems. Intuitive Surgical provides a comprehensive infrastructure of service and support, including installation, repair, maintenance, and training.

Intuitive Surgical has a significant global presence, marketing its products across North America, South America, Europe, Asia-Pacific, the Middle East, and Africa. As of December 31, 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems worldwide, with 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world. In January 2025, Intuitive announced plans to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino by acquiring the da Vinci and Ion distribution businesses in these regions, with the transaction expected to close in 2026. The United States accounts for 65.8% of its net sales.

Intuitive Surgical maintains a strong brand reputation as a pioneer and market leader in robotic-assisted, minimally invasive surgery. The company faces challenges related to tariff concerns, increasing competition, and personnel moves. Despite these, Intuitive Surgical's strong market leadership, continuous innovation, and focus on improving patient care generally uphold a positive brand image.

Intuitive Surgical, Inc. is heavily dominated by institutional owners, who collectively hold a significant portion of the company's shares, approximately 85% to 86%. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and State Street Corp. Individual investors hold approximately 13% to 29.73% of the company's stock, and insiders own under 1% of the company.